[HTML][HTML] Prospective, randomized, double-blind, phase III clinical trial of anti–T-lymphocyte globulin to assess impact on chronic graft-versus-host disease–free survival …
RJ Soiffer, HT Kim, J McGuirk, ME Horwitz… - Journal of Clinical …, 2017 - ncbi.nlm.nih.gov
Journal of Clinical Oncology, 2017•ncbi.nlm.nih.gov
Purpose Several open-label randomized studies have suggested that in vivo T-cell
depletion with anti–T-lymphocyte globulin (ATLG; formerly antithymocyte globulin-
Fresenius) reduces chronic graft-versus-host disease (cGVHD) without compromising
survival. We report a prospective, double-blind phase III trial to investigate the effect of ATLG
(Neovii Biotech, Lexington, MA) on cGVHD-free survival.
depletion with anti–T-lymphocyte globulin (ATLG; formerly antithymocyte globulin-
Fresenius) reduces chronic graft-versus-host disease (cGVHD) without compromising
survival. We report a prospective, double-blind phase III trial to investigate the effect of ATLG
(Neovii Biotech, Lexington, MA) on cGVHD-free survival.
Abstract
Purpose
Several open-label randomized studies have suggested that in vivo T-cell depletion with anti–T-lymphocyte globulin (ATLG; formerly antithymocyte globulin-Fresenius) reduces chronic graft-versus-host disease (cGVHD) without compromising survival. We report a prospective, double-blind phase III trial to investigate the effect of ATLG (Neovii Biotech, Lexington, MA) on cGVHD-free survival.
ncbi.nlm.nih.gov